Lenvatinib Maintenance Therapy After Complete Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: Alternative Strategy in a Resource-limited Setting.
作者信息
Kumar Pramod, Maidur Rohit, Channagiri Adarsh, Patil Chandrashekhar, Krishna Pradeep, Raghavaiah Suresh
机构信息
Hepatology, Gleneagles BGS Hospital, Bengaluru, Karnataka, India.
Medical Gastroenterology, Medicover Hospital, Bengaluru, Karnataka, India.
出版信息
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102455. doi: 10.1016/j.jceh.2024.102455. Epub 2024 Nov 13.
Abstract
摘要
相似文献
1
Lenvatinib Maintenance Therapy After Complete Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: Alternative Strategy in a Resource-limited Setting.在肝细胞癌和门静脉肿瘤血栓形成中，阿替利珠单抗联合贝伐单抗完全缓解后使用乐伐替尼维持治疗：资源有限环境下的替代策略
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102455. doi: 10.1016/j.jceh.2024.102455. Epub 2024 Nov 13.
2
Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.阿替利珠单抗联合贝伐单抗对比乐伐替尼治疗不可切除肝细胞癌的疗效与安全性：一项系统评价和荟萃分析
J Cancer Res Clin Oncol. 2023 Nov;149(17):16191-16201. doi: 10.1007/s00432-023-05342-5. Epub 2023 Sep 2.
3
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis.阿替利珠单抗联合贝伐单抗与乐伐替尼治疗伴门静脉癌栓的肝细胞癌的比较。
J Liver Cancer. 2024 Mar;24(1):81-91. doi: 10.17998/jlc.2023.12.25. Epub 2024 Jan 19.
4
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.阿替利珠单抗联合贝伐珠单抗或仑伐替尼治疗肝细胞癌患者的临床结局：一项多中心真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602. doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
5
Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.乐伐替尼与阿替利珠单抗联合贝伐单抗治疗肝内胆管癌患者的疗效
Anticancer Res. 2025 Mar;45(3):1117-1125. doi: 10.21873/anticanres.17499.
6
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.在高肿瘤负荷的不可切除肝细胞癌中，乐伐替尼和替雷利珠单抗对比阿替利珠单抗和贝伐单抗联合经动脉化疗栓塞性肝动脉灌注化疗：一项多中心回顾性队列研究
Cancer Immunol Immunother. 2025 Feb 1;74(3):88. doi: 10.1007/s00262-025-03942-3.
7
Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series.肝癌患者在使用乐伐替尼后接受阿替利珠单抗联合贝伐单抗治疗出现的甲状腺功能障碍：病例系列报道
SAGE Open Med Case Rep. 2023 Mar 29;11:2050313X231164488. doi: 10.1177/2050313X231164488. eCollection 2023.
8
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.索凡替尼联合贝伐珠单抗治疗后成功转化的肝细胞癌合并门静脉癌栓患者行转化手术：一例报告
World J Surg Oncol. 2022 Jul 12;20(1):228. doi: 10.1186/s12957-022-02691-2.
9
Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.仑伐替尼对比阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌的疗效与安全性：一项系统评价和荟萃分析
Asian Pac J Cancer Prev. 2025 May 1;26(5):1529-1542. doi: 10.31557/APJCP.2025.26.5.1529.
10
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.免疫肿瘤学时代中晚期肝细胞癌的经动脉和靶向治疗的排名：随机索拉非尼对照试验的网络荟萃分析。
Hepatol Commun. 2022 Oct;6(10):2886-2900. doi: 10.1002/hep4.2025. Epub 2022 Jul 4.
本文引用的文献
1
Systemic Therapies for Hepatocellular Carcinoma in India.印度肝细胞癌的全身治疗
J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101440. doi: 10.1016/j.jceh.2024.101440. Epub 2024 May 6.
2
Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report.阿替利珠单抗联合贝伐珠单抗作为门静脉血栓形成的肝细胞癌肝移植降期治疗的初步报告。
Am J Transplant. 2024 Jun;24(6):1087-1090. doi: 10.1016/j.ajt.2024.01.007. Epub 2024 Jan 12.
3
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience.阿替利珠单抗联合贝伐单抗在真实世界中的安全性和有效性：印度的首次经验
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):618-623. doi: 10.1016/j.jceh.2023.02.003. Epub 2023 Feb 10.
4
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.阿替利珠单抗联合贝伐单抗与乐伐替尼治疗不可切除肝细胞癌：一项全球大型真实世界研究。
Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25.
5
Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.索凡替尼联合贝伐珠单抗治疗后成功转化的肝细胞癌合并门静脉癌栓患者行转化手术：一例报告
World J Surg Oncol. 2022 Jul 12;20(1):228. doi: 10.1186/s12957-022-02691-2.
6
Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study.阿替利珠单抗/贝伐珠单抗与乐伐替尼作为不可切除肝细胞癌一线治疗的比较：一项真实世界、多中心研究
Cancers (Basel). 2022 Mar 29;14(7):1747. doi: 10.3390/cancers14071747.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.肝细胞癌合并门静脉癌栓患者的管理：东西比较。
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):721-730. doi: 10.1016/S2468-1253(19)30178-5.
9
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.监测非小细胞肺癌患者纳武利尤单抗免疫动力学的临床意义。
JCI Insight. 2018 Oct 4;3(19):59125. doi: 10.1172/jci.insight.59125.
10
Introduction to checkpoint inhibitors and cancer immunotherapy.检查点抑制剂与癌症免疫疗法简介。
Immunol Rev. 2017 Mar;276(1):5-8. doi: 10.1111/imr.12531.
Zotero 插件